Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.

ABSTRACT:

Background

The standard treatment for patients with advanced transitional cell carcinoma of the bladder is platin based chemotherapy. Only approximately 50% of the patients respond to chemotherapy. Therefore, molecular predictive markers for identification of chemotherapy sensitive subgroups of patients are highly needed. We selected the transcription factor TFAP2α from a previously identified gene expression signature for chemotherapy response.

Methods

TFAP2α expression and localization was assessed by immunohistochemistry using a tissue microarray (TMA) containing 282 bladder cancer tumors from patients with locally advanced (pT2-T4(b) and N(1-3)) or metastatic (M(1)) disease. All patients had received cisplatin containing chemotherapy. Furthermore, QPCR analysis of three

SUBMITTER: Nordentoft I 

PROVIDER: S-EPMC3103475 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature